A French retrospective study suggests that nirsevimab (Beyfortus), used to prevent respiratory syncytial virus (RSV) ...

First-year effectiveness against RSV-LRTI hospitalization remained high (66%–72%) across seasons with different dominant RSV ...

Population-based French study also answers questions about impact on non-RSV infections, a ...

Nirsevimab use reduces antibiotic prescribing for acute respiratory tract infections in infants in both inpatient and outpatient settings.

The study was published in Clinical Infectious Diseases by Mahaa M Ahmed, Children’s Hospital of Philadelphia, Philadelphia, ...

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving them. Factors such as older maternal age, private insurance, and receipt of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Researchers studied real-world data on the effectiveness ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . The findings support CDC’s current recommendations for administration of nirsevimab. Nirsevimab is currently ...

Infants given the monoclonal antibody nirsevimab (Beyfortus) to provide passive immunity against respiratory syncytial virus (RSV) had a lower rate of related hospitalizations and severe outcomes than ...

A single injection of the experimental agent nirsevimab ahead of respiratory syncytial virus (RSV) season protects healthy infants from lower respiratory tract infections associated with the pathogen, ...

Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approved Across all clinical trials, a single dose of nirsevimab delivered ...